MENU CLOSE
About Us

Who We Are

Our Social Responsibility

Events

Exhibitions

Activeties

Members

Hospitals

Individuals

Companies

Member Benefits

 
Bio-medical projectsi

State Key Laboratory of Biotherapy

Cooperation

Achievement Exhibition

Scimea Journals

Signal Transduction and Targeted Therapy

News

News Information

 
Home   >  News
27 Aug 2019
531
Latest News from Member Units | Fluconazole Capsules by Chengdu Brilliant Pharmaceutical Group, The first approved in consistency evaluation in China
Scimea

On February 20, 2019, our company's Fluconazole Capsules were successfully approved for consistency. Our company has carried out comprehensive research into the prescription process, stability, in-vitro dissolution behavior and bioequivalence test of fluconazole capsules. The results show thatour company’s fluconazole capsules are consistent with the original product in terms of quality and therapeutic effect. The approval by the State Drug Administration indicates that the Fluconazole Capsule, another hit product of our company, has been the first to pass the consistency evaluation in China.

 1.jpg1.jpg1.jpg


Product Features

Fluconazole capsules are triazole antifungal drugs for the treatment of Candidiasis, Cryptococcosis and Dermatophytosis. They can also be used to prevent patients susceptible to malignant tumors after cytotoxic chemotherapy or radiotherapy from fungal infections, and treat endemic deep mycosis, Coccidioidomycosis, Coccidioidomycosis, Blastomycosis, Histiocytosis, etc. with normal immune functions.

 



About Chengdu Brilliant Pharmaceutical Group

Founded in 2007, Chengdu Brilliant Pharmaceutical Group is a high-tech enterprise dedicated to the development, production and sales of high-end generic drugs, high-end preparations, innovative drugs and Chinese patent medicines.

For more than a decade, the Group has always adhered to the business philosophy of “Focusing on the pharmaceutical industry development and core competitiveness improvement”, implementing the strategy of combining connotative development with denotative expansion. Internally, the Group attaches great importance to R&D and technology innovation. Externally, it has completed the layout of industrial structure and achieved leap-forward development by virtue of strategic acquisition of target enterprises in the industry. Now the Group has 12 branches (subsidiaries).

At present, having over 3,000 employees, including over 600 R&D personnel, the Group has gradually become a technologically innovative pharmaceutical enterprise with leading R&D capabilities, full range of formulations and varieties, and sound marketing network.


Sichuan University's West China Hospital and Other Units Keep on Recruiting Elite Youth Talents
Internal Training | Expense Payment and Financial Reimbursement Measures
The gynecological urology team of West China Hospital has published important research results on European Urology, a prestigious urological journal
Exploration II: Immersive ICU ‘Battlefield’ Experience in ‘Huaxi ICU Summer Camp’
2nd Notice on 2019 China-Japan Advanced Medical and New Drug R&D Summit Forum & Achievements Transformation Conference
Latest Events Journals News Members About Us Home
Contact Us

Address: No. 1103-1105, Building 6, S2, Global Center, High-tech Zone, Chengdu

Email: scimea@163.com 

Tel: (0086-)028-63859818   

Fax: (0086-)028-63859818   

Contact: (0086-)19113901604 (wechat:19113901604)


Follow Us
Copyright © 2009-2019 SCIMEA. All rights reserved 蜀ICP备19011649号-1